On Tuesday, Shares of Merck & Co. Inc. (NYSE:MRK), gained 0.93% to $57.52.
Merck & Co., known as MSD outside the United States and Canada, recently declared that Pamela J. Craig, stepped down chief financial officer of Accenture, and Dr. Paul B. Rothman, dean of the medical faculty, vice president for medicine of The Johns Hopkins University and chief executive officer of Johns Hopkins Medicine, will join the company’s board of directors, effective Sept. 1, 2015.
The addition expands the Merck board to 14 members. Ms. Craig will serve as a member of the company’s audit committee, and Dr. Rothman will serve as a member of the company’s research committee. They will both stand for election by the company’s shareholders in May 2016.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Shares of Magnum Hunter Resources Corp. (NYSE:MHR), inclined 11.15% to $1.08, during its last trading session.
Magnum Hunter Resources Corporation will host a conference call on Friday, August 7, 2015, at 9:00 a.m. CDT, to talk about its quarter and six months ended June 30, 2015 financial and operating results. The Company will issue a press release announcing these financial and operating results before the U.S. financial markets open on the morning of the conference call.
Magnum Hunter Resources Corporation, an independent oil and gas company, explores for, exploits, acquires, develops, and produces crude oil, natural gas, and natural gas liquid resources in the United States. The company operates through the U.S. Upstream, Midstream, and Oilfield Services segments.
Finally, Fortress Biotech, Inc. (NASDAQ:FBIO), ended its last trade with 3.49% gain, and closed at $3.56.
Fortress Biotech declared that its partner, Altamira Bio, attained from New Zealand Pharmaceuticals Ltd (NZP), a license from the National Institutes of Health (NIH) and Cooperative Research and Development Agreements (CRADAs) for the development of oral N-acetyl-D-mannosamine (ManNAc), a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders. Hyposialylation disorders are a group of pathologies associated with abnormal sialylation of tissues, characteristic of Hereditary Inclusion Body Myopathy (HIBM), also known as GNE myopathy — a rare genetic disorder which causes progressive muscle-wasting and weakness.
New Zealand Pharmaceuticals Ltd (NZP) manufactures ManNAc (DEX-M74) and will remain the exclusive global supplier of ManNAc to Altamira Bio.
Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. The company’s principal pharmaceutical product candidates in clinical development comprise Trichuris suis ova or CNDO-201, a biologic comprising the microscopic eggs of the porcine whipworm for the treatment of autoimmune diseases, such as Crohns disease, ulcerative colitis, or autism spectrum disorder; and CNDO-109, a biologic that activates the immune system’s natural killer cells to seek and destroy cancer cells for the treatment of acute myeloid leukemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
